Zobrazeno 1 - 10
of 406
pro vyhledávání: '"Sonja Zweegman"'
Publikováno v:
Hemato, Vol 2, Iss 1, Pp 116-130 (2021)
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care
Externí odkaz:
https://doaj.org/article/33c01c8ea07e4041822f5d012e1e2948
Autor:
Corien M. Eeltink, RN, Birgit I. Lissenberg-Witte, PhD, Luca Incrocci, PhD, MD, Annemarie M.J. Braamse, PhD, Otto Visser, PhD, MD, Josée Zijlstra, PhD, MD, Irma M. Verdonck-de Leeuw, PhD, Sonja Zweegman, PhD, MD
Publikováno v:
Sexual Medicine, Vol 8, Iss 3, Pp 428-435 (2020)
Introduction: Unambiguous data on sexual dysfunction after Hodgkin lymphoma (HL) treatment are scarce. Aims: To form a baseline in this area, we compared patient-reported sexual function in sexually active male HL survivors in complete remission with
Externí odkaz:
https://doaj.org/article/4e97e848fed04cb2812053d70e1e3d25
Autor:
Mashhour Hosny, Christie P. M. Verkleij, Jort van der Schans, Kristine A. Frerichs, Tuna Mutis, Sonja Zweegman, Niels W. C. J. van de Donk
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 19, p 4593 (2021)
Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor survival. Hence, the development of novel treatment strategies is of great importance. Recently, different classes of immunotherapeutic agents have shown great p
Externí odkaz:
https://doaj.org/article/64f8a5954810435e8491b4a545234db8
Autor:
Laurens E. Franssen, Claudia A. M. Stege, Sonja Zweegman, Niels W. C. J. van de Donk, Inger S. Nijhof
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 4, p 1195 (2020)
Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple myeloma (MM). CD38−directed antibodies have several mechanisms of action. Fc−dependent immune effector mechanisms include complement-dependent cytotoxicity (CDC),
Externí odkaz:
https://doaj.org/article/deff77cb6d6b4ff7a66f92ebf3fe8d41
Autor:
Janneke A J Rood, Birgit I Lissenberg-Witte, Corien Eeltink, Frank Stam, Florence J van Zuuren, Sonja Zweegman, Irma M Verdonck-de Leeuw
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201699 (2018)
The purpose of this study was to investigate the psychometric characteristics (content validity, internal consistency, and subscale structure) of the Hematology Information Needs Questionnaire-62 (HINQ-62), a patient reported outcome measure (PROM) f
Externí odkaz:
https://doaj.org/article/b90f84b66af4494c8bd8893d323ab1cc
Autor:
Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0169828 (2017)
Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging bioma
Externí odkaz:
https://doaj.org/article/aa08a95257eb45329d6e3009ae7b3c4c
Autor:
Monique Terwijn, Wendelien Zeijlemaker, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Willemijn J Scholten, Thomas Pabst, Gregor Verhoef, Bob Löwenberg, Sonja Zweegman, Gert J Ossenkoppele, Gerrit J Schuurhuis
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107587 (2014)
INTRODUCTION: Treatment failure in acute myeloid leukemia is probably caused by the presence of leukemia initiating cells, also referred to as leukemic stem cells, at diagnosis and their persistence after therapy. Specific identification of leukemia
Externí odkaz:
https://doaj.org/article/bb974fdece6b43cb9075d0b0351d519f
Autor:
Gerrit J Schuurhuis, Michael H Meel, Floris Wouters, Lisa A Min, Monique Terwijn, Nick A de Jonge, Angele Kelder, Alexander N Snel, Sonja Zweegman, Gert J Ossenkoppele, Linda Smit
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78897 (2013)
Persistence of leukemic stem cells (LSC) after chemotherapy is thought to be responsible for relapse and prevents the curative treatment of acute myeloid leukemia (AML) patients. LSC and normal hematopoietic stem cells (HSC) share many characteristic
Externí odkaz:
https://doaj.org/article/afdfbec2f3a140adb7a2c8c49ec3e1ce
Autor:
Mark-David Levin, Paula F. Ypma, Sonja Zweegman, Monique C. Minnema, Pieter Sonneveld, Esther G. M. de Waal, Eduardus F. M. Posthuma, Mirian Brink, Kaz Groen, Niels W.C.J. van de Donk, Ellen van der Spek, Avinash G Dinmohamed, Annemiek Broijl
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-7 (2021)
Blood Cancer Journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal
Brink, M, Groen, K, Sonneveld, P, Minnema, M C, Broijl, A, Dinmohamed, A G, van der Spek, E, Levin, M D, Ypma, P F, de Waal, E, Posthuma, E F M W, Zweegman, S & van de Donk, N W C J 2021, ' Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands : a population-based study ', Blood cancer journal, vol. 11, no. 11, 178 . https://doi.org/10.1038/s41408-021-00571-8
Blood cancer journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal, 11(11):178. Nature Publishing Group
Blood Cancer Journal
Brink, M, Groen, K, Sonneveld, P, Minnema, M C, Broijl, A, Dinmohamed, A G, van der Spek, E, Levin, M D, Ypma, P F, de Waal, E, Posthuma, E F M W, Zweegman, S & van de Donk, N W C J 2021, ' Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands : a population-based study ', Blood cancer journal, vol. 11, no. 11, 178 . https://doi.org/10.1038/s41408-021-00571-8
Blood cancer journal, 11(11):178. Nature Publishing Group
Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM
Autor:
Pieter Langerhorst, Joannes F M Jacobs, Martijn M. VanDuijn, Christie P. M. Verkleij, Marina Zajec, Yolanda B. de Rijke, Somayya Noori, Patricia W. C. Bosman, Sonja Zweegman, Theo M. Luider, Niels W.C.J. van de Donk
Publikováno v:
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. De Gruyter
Noori, S, Verkleij, C P M, Zajec, M, Langerhorst, P, Bosman, P W C, de Rijke, Y B, Zweegman, S, Vanduijn, M, Luider, T, van de Donk, N W C J & Jacobs, J F M 2021, ' Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference ', Clinical Chemistry and Laboratory Medicine, vol. 59, no. 12, pp. 1963-1971 . https://doi.org/10.1515/cclm-2021-0399
Clinical Chemistry and Laboratory Medicine, 59, 12, pp. 1963-1971
Clinical Chemistry and Laboratory Medicine, 59, 1963-1971
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. Walter de Gruyter GmbH
Noori, S, Verkleij, C P M, Zajec, M, Langerhorst, P, Bosman, P W C, de Rijke, Y B, Zweegman, S, Vanduijn, M, Luider, T, van de Donk, N W C J & Jacobs, J F M 2021, ' Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: The laboratory solution to eliminate interference ', Clinical Chemistry and Laboratory Medicine, vol. 59, no. 12, pp. 1963-1971 . https://doi.org/10.1515/cclm-2021-0399
Clinical Chemistry and Laboratory Medicine, 59, 12, pp. 1963-1971
Clinical Chemistry and Laboratory Medicine, 59, 1963-1971
Clinical Chemistry and Laboratory Medicine, 59(12), 1963-1971. Walter de Gruyter GmbH
Objectives The therapeutic monoclonal antibody (t-mAb) daratumumab, used to treat multiple myeloma (MM) patients, interferes with routine, electrophoretic based M-protein diagnostics. Electrophoretic response assessment becomes increasingly difficult